Search the Newsreel

Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns

GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary

Geron Corp (GERN) reported its 2026 quarterly results, with revenue increasing to $57.48 million and a net loss of ($16.68 million), resulting in a diluted loss per share of ($0.02). The revenue growth was primarily driven by a 17% quarter-over-quarter increase in product revenue, …

Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative

Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?

In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$20.32 million, while also filing a US$6.03 …

Geron (GERN) Stock May Still Be Below Fair Value On Sales

Geron (GERN) On Earnings And RYTELO Guidance Looks Undervalued

State Street Corporation (GERN) discloses 5.6% beneficial stake in Geron

State Street Corporation has reported a 5.6% beneficial ownership stake in Geron Corp, holding 35,856,671 shares of common stock through its asset management subsidiaries. While State Street holds no sole voting or dispositive power, it maintains shared voting power over 34,097,965 shares and shared …

Geron (NASDAQ:GERN) Posts Earnings Results, Misses Expectations By $0.01 EPS

Geron (NASDAQ:GERN) reported its quarterly earnings, missing analyst EPS expectations by $0.01 with a loss of $0.02 per share, although revenue of $57.48 million surpassed estimates. RYTELO revenue increased 17% year-over-year, and the company anticipates 2026 net product revenue to be at the mid-to-high …

Form 8K Geron Corporation For: 6 August By Investing.com

This article announces the filing of a Form 8K by Geron Corporation on August 6, 2026. The content is brief, primarily serving as a notification of the filing and listing the stock symbol GERN with a daily price change of -5.73%.

Geron reports Q2 2026 RYTELO revenue $57.5M; net loss $16.7M; cash $327M

Geron reported Q2 2026 results, announcing RYTELO net product revenue of $57.5 million and a net loss of $16.7 million. The company ended the quarter with $326.9 million in cash and reaffirmed its full-year 2026 guidance for RYTELO revenue and operating expenses. Geron also …

[10-Q] GERON CORP Quarterly Earnings Report

Geron Corporation (GERN) has released its Q2 2026 quarterly earnings report, detailing financial performance for the period ending June 30, 2026. The report indicates that the company had $326.9 million in cash and securities, a decline from $401.1 million at the end of 2025, …

Geron earnings missed by $0.01, revenue topped estimates

Geron (NASDAQ: GERN) reported second-quarter earnings that missed analyst estimates by $0.01, with an EPS of $-0.0200 against an anticipated $-0.0100. However, the company's revenue surpassed expectations, coming in at $57.48 million compared to the consensus estimate of $55.21 million. Despite the revenue beat, …

Geron Corp (GERN) Shares Surge 16% on Strong Q2 Revenue Beat, De

Geron Releases Q2 2026 Financial Results

Geron Corporation reported a wider-than-expected loss for Q2 2026, with a net loss per share of -$0.02, exceeding the -$0.01 estimate. Despite the loss, the company's oncology therapeutic RYTELO generated $57.5 million in revenue, surpassing estimates and showing significant year-over-year growth. Geron also provided …

Geron stock gains after Q2 revenue beat (GERN:NASDAQ)

Geron (GERN) stock gained 16% after the company reported Q2 2026 revenue that exceeded Street forecasts. This strong performance was driven by sales of its blood cancer therapy, Rytelo. The surge marks Geron's best single-day gain in over two years.

Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates

Geron (GERN) reported a Q2 loss of $0.02 per share, which missed the Zacks Consensus Estimate of a $0.01 loss. However, the company surpassed revenue expectations, posting $57.48 million against an estimate of $55.01 million. Despite the revenue beat, the stock holds a Zacks …

GERON ($GERN) Releases Q2 2026 Earnings

Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, vs. FactSet Est of $55.3M

Geron Corporation announced Q2 revenue of $57.5 million, surpassing the FactSet estimate of $55.3 million. The company also provided earnings guidance for 2026 and reported earnings results for the second quarter and six months ended June 30, 2026. Geron is a commercial-stage biopharmaceutical company …

Earnings Preview: Geron to Report Financial Results Pre-market on August 05

Geron Corporation (GERN) is scheduled to release its financial results on August 5, 2026, before the market opens. Analysts forecast an EPS of -$0.04 and revenue of $4 million for the quarter. Investors will be keenly watching these results to gauge the company's financial …

Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis

Geron Corp (GERN) currently holds a valuation score of 7.81, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The article highlights its P/E ratio of -13.88, which is a significant drop from its recent high, while noting that …

Geron Market Sentiment

This article provides an overview of market sentiment for Geron (GERN), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals show a "Buy" analyst consensus, 12.5% rising short interest, and a bullish options flow with a 0.01 P/C ratio. The …

Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis

Geron Corp (GERN) has a current financial score of 8.58, ranking 41 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 30.89% year-over-year increase, reaching $51.84M, while …

Geron (GERN) Projected to Post Earnings on Wednesday

Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Geron Corp (GERN) by business segments and regional contributions. However, the site states that relevant financial data for these categories have not yet been disclosed by the company. Consequently, no specific revenue figures …

GERN|Geron Corp|Price:1.415|Chg%:-0.035

This article provides a comprehensive stock analysis of Geron Corp (GERN) by TradingKey, highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and recent market outperformance, technical indicators suggest the stock is …

Geron Corp (GERN) Cash Flow

This article provides a detailed historical cash flow statement for Geron Corp (GERN), covering quarterly and annual data for operating, investing, and financing activities. It breaks down various components of cash flow and offers definitions for key financial metrics like operating cash flow, investing …

Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Geron Corp (GERN), listing major shareholders and their proportional holdings, along with a breakdown by shareholder type. It also provides a historical overview of institutional shareholding data and recent shareholder activity, including changes in holdings by key …

TradingKey

This page provides a detailed quarterly and annual income statement for Geron Corp (GERN), allowing users to analyze the company's financial performance and operational efficiency. It presents various financial metrics including revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. …

Geron Corp (GERN) Institutional Confidence

Geron Corp (GERN) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.90%, showing a quarter-over-quarter decrease of 5.14%. Steven Cohen is the largest institutional shareholder, holding 3.19% of the …

Five New Geron Hires Receive Options at $1.44 Per Share

Geron (Nasdaq: GERN) has granted stock options for a total of 202,500 common shares to five new employees, effective July 17, 2026, as an inducement for their employment. The options have an exercise price of $1.44 per share, matching the closing price on the …

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation announced that it granted stock options to five new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover 202,500 shares of common stock, with an exercise price of $1.44 per share, vesting over four years. …

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

Geron Corporation announced it will release its second quarter 2026 financial results and business highlights on Wednesday, August 5, 2026, before the market opens. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a commercial-stage biopharmaceutical …

Geron Schedules 8 a.m. Q2 Conference Call for Aug. 5

Geron (Nasdaq: GERN) announced it will report its second quarter 2026 financial results and business highlights before market open on August 5, 2026. The biopharmaceutical company will also host a conference call and webcast at 8:00 a.m. Eastern Time via its website's Investors and …